DIVISLAB

Price: ₹6,150–6,250 Market Cap: ₹1.65–1.68 lakh Cr P/E: 65–68 (vs industry ~33) ROE: 15–16% ROCE: 18–20% Debt: Almost NIL (D/E ~0.01) API manufacturing (generic + custom synthesis) Long-term contracts with global pharma majors Strong presence in CRAMS + nutraceuticals Revenue & Growth 10-year sales CAGR 12% Last 3-year growth weak (1%) → post-COVID normalization TTM revenue recovery visible (₹10,000+ Cr)